ALK5

Warning: Undefined array key "S1" in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\ALK5.php on line 2
ALK5

LE WE PMID CA

ALK5

2009 1	TGFbeta-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFbeta switch. [19096363] EMBO J 28(2): 88-98 (2009)
2005 2	Gene expression profiling demonstrates that TGF-beta1 signals exclusively through receptor complexes involving Alk5 and identifies targets of TGF-beta signaling. [15769904] Physiol Genomics 21(3): 396-403 (2005)
2009 3	Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline. [19116361] Am J Pathol 174(2): 380-9 (2009)
2008 4	Transforming growth factor-beta1 protects against pulmonary artery endothelial cell apoptosis via ALK5. [18456797] Am J Physiol Lung Cell Mol Physiol 295(1): L123-33 (2008)
2006 5	Nonoverlapping expression patterns of ALK1 and ALK5 reveal distinct roles of each receptor in vascular development. [16344855] Lab Invest 86(2): 116-29 (2006)
2006 6	TGFbeta1 induces vasculogenesis and inhibits angiogenic sprouting in an embryonic stem cell differentiation model: respective contribution of ALK1 and ALK5. [17071858] Stem Cells 24(11): 2420-7 (2006)
2009 7	TGF-beta inhibits vascular sprouting through TGF-beta type I receptor in the mouse embryonic aorta. [19398875] Tohoku J Exp Med 218(1): 63-71 (2009)
2005 8	Matrix contraction by dermal fibroblasts requires transforming growth factor-beta/activin-linked kinase 5, heparan sulfate-containing proteoglycans, and MEK/ERK: insights into pathological scarring in chronic fibrotic disease. [16314481] Am J Pathol 167(6): 1699-711 (2005)
1998 9	Enhanced expression of transforming growth factor-beta type I and type II receptors in wound granulation tissue and hypertrophic scar. [9466575] Am J Pathol 152(2): 485-93 (1998)
2006 10	Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. [16575856] Arthritis Rheum 54(4): 1309-16 (2006)
1994 11	TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. [7806579] J Cell Biol 127(6 Pt 2): 2021-36 (1994)
1999 12	TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. [10574705] J Cell Sci 112 ( Pt 24)(-): 4557-68 (1999)
2008 13	Signaling via the Tgf-beta type I receptor Alk5 in heart development. [18718461] Dev Biol 322(1): 208-18 (2008)
2007 14	Endoglin and Alk5 regulate epithelial-mesenchymal transformation during cardiac valve formation. [17250821] Dev Biol 304(1): 420-32 (2007)
2006 15	Epithelial and ectomesenchymal role of the type I TGF-beta receptor ALK5 during facial morphogenesis and palatal fusion. [16806156] Dev Biol 296(2): 298-314 (2006)
2006 16	Transforming growth factor-beta induces loss of epithelial character and smooth muscle cell differentiation in epicardial cells. [16258965] Dev Dyn 235(1): 82-93 (2006)
2006 17	Transforming growth factor-beta stimulates epithelial-mesenchymal transformation in the proepicardium. [16245329] Dev Dyn 235(1): 50-9 (2006)
2008 18	Signaling through Tgf-beta type I receptor Alk5 is required for upper lip fusion. [18586087] Mech Dev 125(9-10): 874-82 (2008)
2006 19	Defective ALK5 signaling in the neural crest leads to increased postmigratory neural crest cell apoptosis and severe outflow tract defects. [17078885] BMC Dev Biol 6(): 51 (2006)
2000 20	Functional analysis of the TGFbeta receptor/Smad pathway through gene ablation in mice. [10853822] Int J Dev Biol 44(3): 253-65 (2000)
2008 21	Cancer-associated transforming growth factor beta type II receptor gene mutant causes activation of bone morphogenic protein-Smads and invasive phenotype. [18339844] Cancer Res 68(6): 1656-66 (2008)
2003 22	Disease-associated mutations in conserved residues of ALK-1 kinase domain. [12700602] Eur J Hum Genet 11(4): 279-87 (2003)
2005 23	Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. [15563636] Am J Respir Crit Care Med 171(8): 889-98 (2005)
2007 24	SB-431542, a transforming growth factor beta inhibitor, impairs Trypanosoma cruzi infection in cardiomyocytes and parasite cycle completion. [17526757] Antimicrob Agents Chemother 51(8): 2905-10 (2007)
2008 25	SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. [18202322] Arterioscler Thromb Vasc Biol 28(4): 665-71 (2008)
2004 26	Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts. [15593186] Arthritis Rheum 50(12): 4008-21 (2004)
2008 27	Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. [18474728] Blood 112(8): 3434-43 (2008)
2005 28	Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. [15723089] Br J Pharmacol 145(2): 166-77 (2005)
2007 29	A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. [17332368] Cancer Res 67(5): 2351-9 (2007)
2003 30	SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells. [14633705] Cancer Res 63(22): 7791-8 (2003)
2007 31	Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats. [17505012] Clin Cancer Res 13(10): 3087-99 (2007)
2008 32	TGFbeta induces SIK to negatively regulate type I receptor kinase signaling. [18725536] J Cell Biol 182(4): 655-62 (2008)
2006 33	Intracellular TGF-beta receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo. [16741519] J Invest Dermatol 126(8): 1733-44 (2006)
2005 34	Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis. [15769863] J Pharmacol Exp Ther 313(3): 943-51 (2005)
2004 35	SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. [14978253] Mol Pharmacol 65(3): 744-52 (2004)
2002 36	SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. [12065756] Mol Pharmacol 62(1): 65-74 (2002)
2002 37	Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. [12065755] Mol Pharmacol 62(1): 58-64 (2002)
2008 38	Inhibitory effect of blocking TGF-beta/Smad signal on injury-induced fibrosis of corneal endothelium. [19081766] Mol Vis 14(): 2272-81 (2008)
2006 39	Growth differentiation factor 11 signals through the transforming growth factor-beta receptor ALK5 to regionalize the anterior-posterior axis. [16845371] EMBO Rep 7(8): 831-7 (2006)
2004 40	Growth differentiation factor-9 signaling is mediated by the type I receptor, activin receptor-like kinase 5. [14684852] Mol Endocrinol 18(3): 653-65 (2004)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\ALK5.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\ALK5.php on line 92